Minya University | Egypt

Dr. Marwa Monier Mahmoud Refaie is an esteemed Egyptian pharmacologist and academician currently serving as an Assistant Professor in the Department of Pharmacology, Faculty of Medicine, Minia University. With an H-index of 18 on both Scopus and Google Scholar, she has made impactful contributions to pharmacological research, particularly in drug safety, toxicology, and disease treatment models. Born on July 2, 1983, in Mallawi, El-Minia, Dr. Refaie balances her thriving career with family life, being a proud mother of three sons.

Professional profile👤

Google Scholar

Scopus

ORCID

Strengths for the Awards✨

Dr. Marwa Monier Mahmoud Refaie demonstrates a remarkable profile that aligns seamlessly with the ethos of the Pioneer Researcher Award. With over 16 years of academic and research experience in pharmacology, she has established herself as a thought leader in experimental and clinical pharmacology, especially in toxicology, nephroprotection, cardioprotection, and hormonal therapy research.

Her impressive H-index of 18 (Scopus & Google Scholar) reflects the consistent impact of her work on the scientific community. Dr. Refaie has authored over 40 international publications, many in high-impact journals, and has investigated novel therapeutic mechanisms for critical conditions like nephrotoxicity, PCOS, and ischemia-reperfusion injuries. Her robust experimental skill set, prolific mentorship of postgraduate students, and service on editorial boards of globally recognized journals (e.g., British Journal of Pharmacology, Elsevier journals) reflect both leadership and innovation in her field. Moreover, her multiple awards from Minia University for international publication over consecutive years affirm her consistency and excellence in pioneering pharmacological research.

🎓 Education

Dr. Refaie began her academic journey at Minia University, earning her MBBS in Medicine and Surgery in 2006. She further specialized in pharmacology, completing her Master’s in 2011 and a Ph.D. in Basic and Clinical Pharmacology in 2016. Expanding her interdisciplinary expertise, she also earned a Diploma in Infection Control in 2021, highlighting her dedication to integrated healthcare education and safety.

🧪 Experience

With over 16 years of academic and research experience, Dr. Refaie has evolved from a Demonstrator to Assistant Professor at Minia University. Her work spans teaching basic and clinical pharmacology to medical, dental, pharmacy, and nursing students, and supervising numerous M.Sc. and Ph.D. theses. Her research explores pharmacotherapy, cancer, autoimmune diseases, and drug safety, and she has actively contributed to institutional accreditation, infection control, and community healthcare education.

🔬 Research Interests On Medicine and Health Sciences

Dr. Refaie’s research is driven by a passion for understanding and combating toxicological and precancerous conditions. Her focus lies in modeling and treating organ-specific toxicity, ischemia-reperfusion injuries, and hyperplastic lesions. Her work also explores novel mechanisms of cardioprotection, reproductive toxicity, and immunomodulation using pharmacological agents such as diacerein, fenofibrate, and SGLT2 inhibitors.

🏆 Awards

Dr. Refaie has received consistent recognition for her excellence in research and publication. She was awarded first place at the 57th Annual Conference of the Egyptian Society of Pharmacology and Experimental Therapeutics (2018). Additionally, she has received Minia University’s International Publication Award for six consecutive years (2019–2024), reflecting her sustained contributions to global pharmacological science.

📚 Publications

Effect of coenzyme‐Q10 on doxorubicin‐induced nephrotoxicity in rats
AAK El-Sheikh, MA Morsy, MM Mahmoud, RA Rifaai, AM Abdelrahman
2012 – Cited by: 147
Possible protective effect of diacerein on doxorubicin‐induced nephrotoxicity in rats
MMM Refaie, EF Amin, NF El-Tahawy, AM Abdelrahman
2016 – Cited by: 96
Mechanism mediating the protective effect of diacerein in ischemia-reperfusion-induced testicular injury in rats
SA Abdel-Gaber, RK Mohammed, MMM Refaie
2018 – Cited by: 62
Protective mechanisms of coenzyme-Q10 may involve up-regulation of testicular P-glycoprotein in doxorubicin-induced toxicity
AAK El-Sheikh, MA Morsy, MM Mahmoud, RA Rifaai
2014 – Cited by: 52
Naringenin palliates cisplatin and doxorubicin gonadal toxicity in male rats
AA Fouad, MMM Refaie, MI Abdelghany
2019 – Cited by: 50
The role of interleukin‐1β and its antagonist (diacerein) in estradiol benzoate‐induced endometrial hyperplasia and atypia in female rats
MMM Refaie, M El‐Hussieny
2017 – Cited by: 48
Role of ATP-Sensitive Potassium Channel (KATP) and eNOS in Mediating the Protective Effect of Nicorandil in Cyclophosphamide-Induced Cardiotoxicity
MMM Refaie, S Shehata, M El-Hussieny, WM Abdelraheem, …
2020 – Cited by: 46
Assessment of Antibacterial and Anti-biofilm Effects of Vitamin C Against Pseudomonas aeruginosa Clinical Isolates
WM Abdelraheem, MMM Refaie, RKM Yousef, AS Abd El Fatah, …
2022 – Cited by: 44
Protective role of nebivolol in cadmium-induced hepatotoxicity via downregulation of oxidative stress, apoptosis and inflammatory pathways
MMM Refaie, M El-Hussieny, NM Zenhom
2018 – Cited by: 43
Protective effect of pioglitazone on ovarian ischemia reperfusion injury of female rats via modulation of peroxisome proliferator activated receptor gamma and heme-oxygenase 1
MMM Refaie, M El-Hussieny
2018 – Cited by: 41

📝 Conclusion

🌟 Dr. Marwa M. Refaie exemplifies excellence in academic pharmacology through her sustained research, impactful publications, and commitment to medical education. Her work spans cutting-edge experimental pharmacology, disease modeling, and immunotherapy. Her consistent accolades, active international collaborations, and editorial contributions to top journals affirm her candidacy as a distinguished nominee for prestigious research awards. Her legacy in pharmacological sciences continues to inspire and uplift the global scientific community.

Yijun Zheng | Medicine | Best Researcher Award

Posted on 28/04/202528/04/2025 by Forensic Scientist

Mr. Yijun Zheng | Medicine | Best Researcher Award

The Second Hospital & Clinical Medical School, Lanzhou University | China

Dr. Zheng Yijun is a dedicated medical researcher currently pursuing a PhD in Surgery at Lanzhou University. With a strong focus on the pharmacological actions of traditional Chinese medicine in cancer treatment, particularly gastric cancer, he has contributed to multiple papers, including two independent SCI publications. Dr. Zheng also serves as a reviewer for high-impact journals like Frontiers in Medicine and International Journal of Clinical Practice. He is actively involved in projects funded by the National Natural Science Foundation of China and collaborates on key provincial research initiatives.

Professional profile👤

Scopus

Strengths for the Awards✨

Strong Research Focus: Zheng has a clear focus on the prevention and treatment of gastric cancer through traditional Chinese medicine, a significant and relevant area of study in modern healthcare.
Academic Contributions: Zheng has independently authored two SCI papers, one of which has achieved a high citation rate, highlighting the impact of their work in the academic community.
Collaborative Research: Zheng has been involved in eight research projects, including two funded by the National Natural Science Foundation of China, which demonstrates involvement in high-impact research.
Peer Review Contributions: Serving as a reviewer for reputable journals such as SCI and Frontiers in Medicine showcases the recognition of Zheng’s expertise and their ability to contribute to the broader academic community.
Zheng Yijun demonstrates strong academic research in a promising and highly relevant field. With a focus on traditional Chinese medicine for cancer treatment, significant publications, and involvement in prestigious research projects, Zheng is well-positioned for consideration for the “Best Researcher Award.” However, expanding the breadth of their research network, increasing publication output, and gaining editorial experience would help to further solidify their candidacy for this award.

Education 🎓

Dr. Zheng is currently enrolled in the PhD program in Surgery at Lanzhou University. His academic journey is complemented by his extensive participation in research, including a review of Astragalus Polysaccharide’s pharmacological effects, published in Frontiers in Pharmacology. He has independently authored SCI papers that contribute to the field of traditional medicine’s role in cancer treatment.

Experience 💼

Dr. Zheng has participated in over eight research projects, two of which were funded by the National Natural Science Foundation of China. His work spans across the investigation of gastric cancer treatment and the pharmacological effects of traditional Chinese medicine. Additionally, Dr. Zheng has served as a reviewer for multiple high-impact journals, solidifying his expertise and credibility in the field.

Research Interest On Medicine 🔬

Dr. Zheng’s primary research interest is in the prevention and treatment of gastric cancer through traditional Chinese medicine. His research aims to provide a theoretical foundation for incorporating traditional medicine in cancer therapy, with a specific focus on polysaccharides and their pharmacological actions in tumor treatment.

Award 🏆

Dr. Zheng is a nominee for the Best Researcher Award at the Forensic Scientist Awards, due to his significant contributions to the field of medical research, particularly in the application of traditional Chinese medicine for tumor treatment. His innovative work and high citation rate highlight his impact in medical research.

Publications 📚

Zheng Y, Ren W, Zhang L, Zhang Y, Liu D, Liu Y. “A Review of the Pharmacological Action of Astragalus Polysaccharide.” Front Pharmacol. 2020 Mar 24; 11:349. Link
- Cited by: 348 articles (SCI citation)
Zheng Y, Zhang Y, Wang Z, Guo X, Zhang L, Zhang Y. “Multiple data sets to explore the key molecules and mechanism of lymph node metastasis in gastric cancer.” Discov Oncol. 2025 Apr 24; 16(1):606. Link
- Cited by: 98 articles (SCI citation)

Conclusion 🌍

Dr. Zheng Yijun is an emerging leader in the field of medical research, particularly in the application of traditional Chinese medicine for cancer treatment. His dedication to advancing the understanding of gastric cancer and its treatment methods has already resulted in significant publications and recognition. As a nominee for the Best Researcher Award, his future in medical research looks promising, with continued contributions to the development of effective cancer therapies.

Youngji Jo | Medicine | Best Researcher Award

Posted on 15/02/202515/02/2025 by Forensic Scientist

Dr. Youngji Jo | Medicine | Best Researcher Award

Assistant Professor | UConn Health | United States

Dr. Youngji Jo is an esteemed researcher and academic with a profound background in public health sciences, epidemiology, and health systems modeling. She currently serves as an Assistant Professor in the Department of Public Health Science at the University of Connecticut (UConn Health), USA. With a wealth of experience in infectious disease modeling, health economics, and digital health, Dr. Jo has made significant contributions to global health research, particularly in tuberculosis (TB), HIV, and COVID-19 studies. Her interdisciplinary expertise bridges epidemiology, policy evaluation, and data-driven decision-making.

Profile👤

ORCID

Scopus

Google Scholar

Strengths for the Awards✨

✅ Outstanding Research Contributions: Dr. Youngji Jo has an extensive research portfolio, with expertise in epidemiology, infectious disease modeling, digital health, and public health interventions. She has made significant contributions to tuberculosis (TB) and HIV/AIDS research, as well as COVID-19 modeling, demonstrating her impact on global health policy and disease control.

✅ Strong Funding and Grant Record: She has secured multiple prestigious grants, including from the NIH (F32 Fellowship), Bill & Melinda Gates Foundation, and Korea Disease Control and Prevention Agency. Her ability to attract competitive funding highlights the recognition of her work in the scientific community.

✅ Interdisciplinary and Global Research Impact: Her work spans multiple countries, including the U.S., South Korea, India, Bangladesh, and Nigeria. She has collaborated with top institutions such as Johns Hopkins University, Boston Medical Center, Korea University, and the WHO, indicating a strong global research network.

✅ Applied and Policy-Relevant Research: Her projects focus on real-world impact, such as cost-effectiveness of public health interventions, mathematical modeling of infectious diseases, and policy development for pandemics. This makes her research highly relevant to public health decision-making.

✅ Recognition and Awards: She has received several competitive scholarships and fellowships, such as the NIH Fellowship, WHO-JHU Global mHealth Initiative Scholarship, and conference awards from the International AIDS Society and CROI, reflecting her academic excellence.

Education 🎓

Dr. Jo earned her Ph.D. in Health Systems from the International Health Department at Johns Hopkins Bloomberg School of Public Health, USA. Her doctoral dissertation focused on the cost-effectiveness and scalability of an mHealth intervention to improve pregnancy surveillance in rural Bangladesh. She further enhanced her expertise with post-doctoral fellowships at Boston Medical Center and Johns Hopkins Bloomberg School of Public Health, specializing in infectious disease modeling and health systems research. She holds an M.A. in International Economics & International Relations from Johns Hopkins School of Advanced International Studies (SAIS) and a B.E. in Electrical Engineering from Seoul National University, South Korea.

Experience 💼

Dr. Jo’s extensive research career includes roles as a Post-Doctoral Fellow at Boston University, where she investigated the intersection of HIV and TB care delivery. She has served as a Research Scientist at the Bill & Melinda Gates Foundation, developing agent-based stochastic TB models. Additionally, she has collaborated with global institutions such as the Korea Disease Control and Prevention Agency, RIGHT Foundation, and WHO, contributing to the development of health technologies, pandemic policy evaluations, and mathematical modeling for infectious diseases.

Research Interests On Medicine 📝

Dr. Jo’s research spans multiple critical areas of public health, including:

Infectious disease modeling (TB, HIV, COVID-19)
Health economics and cost-effectiveness analysis
Digital health interventions and mHealth solutions
Global health policy evaluation
Big data and artificial intelligence applications in epidemiology

Awards & Honors 🏆

Dr. Jo has received numerous accolades for her contributions to public health research, including:

Pre-K Junior Faculty Career Development Award (2022-Present)
NIH F32 Individual Fellowship Grant (2020-2022)
International AIDS Society Conference Scholarship (2021)
Gordis Teaching Fellowship at Johns Hopkins University (2014)
WHO-JHU Global mHealth Initiative Scholarship (2012)
Japan Student Services Organization (JASSO) Government Scholarship (2005-2006)

Publications 📚

Dr. Jo has published extensively in high-impact journals. Some of her recent publications include:

Integrated multi‐month dispensing for HIV and hypertension in South Africa: A model of epidemiological impact and cost‐effectiveness
- Year: 2025
- Authors: Youngji Jo, Sydney Rosen, Brooke E. Nichols, Lise Jamieson, Nkgomeleng Lekodeba, Robert Horsburgh, Jr.
Nationwide Target Trial Emulation Evaluating the Clinical Effectiveness of Oral Antivirals for COVID-19 in Korea
- Year: 2024
- Authors: Kyungmin Huh, Youngji Jo, Gi Hwan Bae, Hyejin Joo, Munkhzul Radnaabaatar, Hyungmin Lee, Jungyeon Kim, Dong-Hwi Kim, Min-Gyu Yoo, Il Uk Jo et al.
Antenatal care in rural Bangladesh: current state of costs, content and recommendations for effective service delivery
- Authors: Y Jo, K Alland, H Ali, S Mehra, AE LeFevre, S Pak, S Shaikh, P Christian, …
- Year: 2019
- Citations: 62
Using the lives saved tool (LiST) to model mHealth impact on neonatal survival in resource-limited settings
- Authors: Y Jo, AB Labrique, AE Lefevre, G Mehl, T Pfaff, N Walker, IK Friberg
- Year: 2014
- Citations: 59
Cost-effectiveness of remdesivir and dexamethasone for COVID-19 treatment in South Africa
- Authors: Y Jo, L Jamieson, I Edoka, L Long, S Silal, JRC Pulliam, H Moultrie, …
- Year: 2021
- Citations: 57
Drinking and driving in Vietnam: public knowledge, attitudes, and practices
- Authors: NT Tran, AM Bachani, VC Pham, JC Lunnen, Y Jo, J Passmore, …
- Year: 2012
- Citations: 49
Model-based cost-effectiveness of state-level latent tuberculosis interventions in California, Florida, New York, and Texas
- Authors: Y Jo, S Shrestha, I Gomes, S Marks, A Hill, G Asay, D Dowdy
- Year: 2021
- Citations: 37
Forecasting the value for money of mobile maternal health information messages on improving utilization of maternal and child health services in Gauteng, South Africa: cost …
- Authors: A LeFevre, MA Cabrera-Escobar, D Mohan, J Eriksen, D Rogers, …
- Year: 2018
- Citations: 26
Model-based cost-effectiveness analysis of oral antivirals against SARS-CoV-2 in Korea
- Authors: Y Jo, SB Kim, M Radnaabaatar, K Huh, JH Yoo, KR Peck, H Park, J Jung
- Year: 2022
- Citations: 23
Costs and cost-effectiveness analyses of mCARE strategies for promoting care seeking of maternal and newborn health services in rural Bangladesh
- Authors: Y Jo, AE LeFevre, K Healy, N Singh, K Alland, S Mehra, H Ali, S Shaikh, …
- Year: 2019
- Citations: 23

Conclusion 🔖

Dr. Youngji Jo is a distinguished academic and researcher whose interdisciplinary expertise continues to shape the landscape of global public health. Her contributions to infectious disease modeling, health economics, and digital health interventions have significantly advanced our understanding of TB, HIV, and COVID-19. As she continues her research at UConn Health, her work remains at the forefront of data-driven solutions for global health challenges.

Kyaw Thein | Health Sciences | Best Researcher Award

Posted on 21/12/202421/12/2024 by Forensic Scientist

Assist. Prof. Dr. Kyaw Thein | Health Sciences | Best Researcher Award

MD | Comprehensive Cancer Centers of Nevada – Central Valley | United States

Dr. Kyaw Zin Thein, MD, is a highly skilled Medical Oncologist and Hematologist currently practicing at the Central Valley Treatment Center – Twain, affiliated with the Comprehensive Cancer Centers of Nevada. He also serves as a Clinical Assistant Professor at Touro University Nevada (TUN) and the University of Nevada, Las Vegas (UNLV). His dedication to patient care, research, and education has solidified his reputation as a leader in precision oncology and hematology.

Profile

Scopus

Google scholar

Orcid

Strengths for the Awards

Impressive Academic and Clinical Training
- Dr. Kyaw Zin Thein has a robust academic background, including advanced fellowships in hematology, oncology, and investigational cancer therapeutics at world-renowned institutions such as MD Anderson Cancer Center.
- A double board-certified oncologist and hematologist with certifications valid through 2029, showcasing his extensive expertise and commitment to maintaining professional standards.
Research Contributions and Publications
- Author of 53 peer-reviewed journal articles, demonstrating significant contributions to advancing knowledge in oncology and hematology.
- Published book chapters on cutting-edge topics like poly (ADP-ribose) polymerase inhibitors and multidisciplinary paradigms for head and neck cancer, reflecting his thought leadership in the field.
Teaching and Mentorship
- Active roles as Clinical Assistant Professor at UNLV and Touro University Nevada, contributing to medical education.
- Mentorship of numerous trainees, ranging from medical students to fellows, highlighting his commitment to shaping the next generation of oncologists and researchers.
Leadership and Awards
- Held leadership roles, including Chief Fellow, Chief Resident, and committee member positions at esteemed institutions.
- Recipient of multiple awards, such as the ASH Abstract Achievement Award and Research Recognition Awards, underscoring his excellence in research and clinical practice.

Education 🎓

Dr. Thein completed his M.B., B.S. (Doctor of Medicine) at the Institute of Medicine 1, Yangon, Myanmar (2004–2010). His advanced training includes:

Residency in Internal Medicine at Kingsbrook Jewish Medical Center, NY (2012–2015).
Fellowship in Hematology & Medical Oncology at Texas Tech University Health Sciences Center, TX (2016–2019).
Advanced Fellowships in Investigational Cancer Therapeutics and Oncologic Emergency Medicine at the University of Texas MD Anderson Cancer Center (2015–2020).

Professional Experience 💼

Dr. Thein has held numerous prestigious positions:

Medical Oncologist/Hematologist, Central Valley Treatment Center, Nevada (2023–present).
Assistant Professor of Medicine, Division of Hematology and Medical Oncology, Oregon Health & Science University (OHSU) (2020–2023).
Chief Fellow, Texas Tech University Health Sciences Center (2018–2019).
Member of multiple professional committees, including the Knight Cancer Institute’s Data and Safety Monitoring Committee.

Research Interests On Health Sciences🔬

Dr. Thein’s research focuses on precision oncology, investigational cancer therapeutics, and immunotherapy. He has contributed extensively to advancing cancer care through his work on targeted therapies, combination regimens, and innovative diagnostic methods.

Awards & Recognitions 🏆

Dr. Thein has received numerous accolades, including:

ASH Abstract Achievement Award, American Society of Hematology (2016).
Research Recognition Awards from Kingsbrook Jewish Medical Center (2014, 2015).
Excellence in Education Award, Myanmar American Medical Education Society (2011).

Publications 📚

Copper deficiency anemia
- Authors: ZW Myint, TH Oo, KZ Thein, AM Tun, H Saeed
- Year: 2018
- Citations: 298
9p21 loss confers a cold tumor immune microenvironment and primary resistance to immune checkpoint therapy
- Authors: G Han, G Yang, D Hao, Y Lu, K Thein, BS Simpson, J Chen, R Sun, et al.
- Year: 2021
- Citations: 136
Precision therapy for RET-altered cancers with RET inhibitors
- Authors: KZ Thein, V Velcheti, BHM Mooers, J Wu, V Subbiah
- Year: 2021
- Citations: 112
Adverse effects of immune checkpoint therapy in cancer patients visiting the emergency department of a comprehensive cancer center
- Authors: I El Majzoub, A Qdaisat, KZ Thein, MA Win, MM Han, K Jacobson, et al.
- Year: 2019
- Citations: 91
Acute symptomatic hypocalcemia from immune checkpoint therapy-induced hypoparathyroidism
- Authors: MA Win, KZ Thein, A Qdaisat, SCJ Yeung
- Year: 2017
- Citations: 83
The contemporary management of cancers of the sinonasal tract in adults
- Authors: R Thawani, MS Kim, A Arastu, Z Feng, MT West, NF Taflin, KZ Thein, R Li, et al.
- Year: 2023
- Citations: 74
Clinical and Molecular Characterization of POLE Mutations as Predictive Biomarkers of Response to Immune Checkpoint Inhibitors in Advanced Cancers
- Authors: B Garmezy, J Gheeya, HY Lin, Y Huang, T Kim, X Jiang, KZ Thein, et al.
- Year: 2022
- Citations: 74
Therapeutics targeting mutant KRAS
- Authors: KZ Thein, AB Biter, DS Hong
- Year: 2021
- Citations: 55
Pernicious anemia: Pathophysiology and diagnostic difficulties
- Authors: TW Htut, KZ Thein, TH Oo
- Year: 2021
- Citations: 52
Venous thromboembolism risk in patients with hormone receptor-positive HER2-negative metastatic breast cancer treated with combined CDK 4/6 inhibitors plus endocrine therapy
- Authors: KZ Thein, TW Htut, S Ball, S Swarup, A Sultan, TH Oo
- Year: 2020
- Citations: 45

Conclusion 🌟

Dr. Kyaw Zin Thein is a visionary leader in oncology and hematology, with a career distinguished by cutting-edge research, impactful teaching, and exceptional clinical care. His dedication to advancing cancer therapies and mentoring future medical professionals underscores his commitment to transforming cancer treatment and education worldwide.

Silvia Di Bonaventura | Health Sciences | Young Scientist Award

Posted on 04/12/202404/12/2024 by Forensic Scientist

Ms. Silvia Di Bonaventura | Health Sciences | Young Scientist Award

Lecturer-Researcher | Rey Juan Carlos University | Spain

Silvia Di Bonaventura is a passionate researcher, professor, and social entrepreneur with a commitment to advancing scientific innovation. Her journey reflects an insatiable curiosity, strong leadership, and dedication to contributing to transformative projects in health and biomedicine. Fluent in five languages, she combines global perspectives with academic rigor and entrepreneurial vision to address complex challenges in research and healthcare.

Profile:

Orcid

Strengths for the Awards:

Academic Excellence:
Silvia’s strong academic foundation includes degrees in Physiotherapy, Invasive Physiotherapy, and an ongoing PhD in Pain Research, coupled with a Master’s in Clinical Research at Harvard University, showcasing her commitment to scientific rigor and innovation.
Research Contributions:
Silvia has demonstrated significant contributions to pain research, with notable publications on neuromodulation and digital health interventions for chronic pain. Her work combines clinical relevance and innovative methodologies, emphasizing her potential to make lasting impacts in biomedicine.
Global Collaborations:
Her experiences as an Invited Researcher at Vrije Universiteit Brussels and Harvard Medical School reflect her ability to work on international research collaborations, contributing to the advancement of cutting-edge medical technologies.
Entrepreneurial Leadership:
As the CEO of Bei (a digital health app for fibromyalgia) and the Founder of PainCorp, Silvia has effectively bridged research with practical healthcare solutions, emphasizing her visionary approach and ability to create real-world impact.
Awards and Recognitions:
Silvia’s accolades, including the Banco Santander Scholarship, Young Emerging Leader 2022, and the Outstanding Leadership Award, highlight her dedication, leadership, and exceptional achievements in the field.
Multilingual Communication Skills:
Fluent in five languages, Silvia has the ability to collaborate and communicate effectively across diverse cultures, enhancing her research’s global reach and impact.

🎓Education

Diploma in Computer Science (2009–2014)
Instituto Técnico Industrial “IIS” – TE
Degree in Physiotherapy (2014–2018)
Universidad Alfonso X El Sabio
Master’s Degree in Invasive Physiotherapy (2017–2018)
Universidad Camilo José Cela
Master’s Degree in Clinical Research (2024–2024)
Harvard University
PhD in Pain Research (2021–Present)
Universidad Rey Juan Carlos

💼Experience

Physiotherapist & Co-Director
Clínica Gatzambide (2018–2022)
Led a successful physiotherapy practice focused on personalized patient care.
Professor & Researcher
Rey Juan Carlos University (2021–Present)
Teaching and conducting groundbreaking research in pain management.
Invited Researcher
Vrije Universiteit Brussels (2023) & Harvard Medical School (2024)
Advanced research on neuromodulation and pain mechanisms.
Entrepreneurial Roles
- CEO & Founder of Bei (2024–Present): Innovating solutions for fibromyalgia self-management.
- President of PainCorp (2024–Present): Dedicated to pain research and treatment.
- Research Fellow at Mit LinQ and Harvard (2024–Present): Driving forward collaborative research initiatives.

🔬Research Interests On Health Sciences

Silvia’s research centers on pain management, clinical research, neuromodulation, and digital health solutions. She is particularly focused on designing innovative interventions for chronic pain conditions such as fibromyalgia, combining scientific rigor with practical applications for patient care.

🏆Awards

Top 15 Graduates in Spain (Physiotherapy Ranking)
Banco Santander Scholarship (Best Academic Record)
PI in Competitive Funding (Biomedicine Research)
Entrepreneurship Babson College Scholarship
Nova Talent Member
Young Emerging Leader ’22 (Korea World Summit)
Outstanding Leadership Award (Harbour Space University)

🥇Achievements & Certifications

Recognized as one of the Top 15 Graduates in Spain in Physiotherapy.
Awarded Banco Santander Scholarship for academic excellence.
Recipient of Babson College Entrepreneurship Scholarship for advancing digital health solutions.
Certified in Italian (Native), Spanish (C2), English (C1), French (B1), and Chinese (HSK2).

🌍Final Note

Silvia Di Bonaventura exemplifies a modern researcher blending academic excellence, global collaboration, and entrepreneurship. Through her multifaceted roles, she seeks to bridge the gap between research and real-world impact, paving the way for transformative solutions in healthcare.

Publication Top Note’s

“How Does Conditioned Pain Modulation Influence Motor Imagery Processes in Women with Fibromyalgia Syndrome? A Cross-Sectional Study Secondary Analysis”

Authors: Víctor Riquelme-Aguado, Silvia Di-Bonaventura, María Elena González-Álvarez, Alazne Zabarte-Del Campo, Josué Fernández-Carnero, Antonio Gil-Crujera, Francisco Gómez-Esquer, Jorge Hugo Villafañe
Journal: Journal of Clinical Medicine
Year: 2024

“The Link between Endogenous Pain Modulation Changes and Clinical Improvement in Fibromyalgia Syndrome: A Meta-Regression Analysis”

Authors: Kevin Pacheco-Barrios, Rafaela Machado Filardi, Luis Fernando González-González, Nayeon Park, Fernanda Queiroz Petrus, Alba Navarro-Flores, Silvia Di-Bonaventura, Luana Gola Alves, Fernanda Queiroz, Felipe Fregni
Journal: Biomedicines
Year: 2024

“Perceived Benefits and Limitations of a Psychoeducation Program for Patients with Fibromyalgia: An Interpretative Phenomenological Analysis”

Authors: Silvia Di-Bonaventura, Raúl Ferrer-Peña, Joaquín Pardo-Montero, Josué Fernández-Carnero, Roy La Touche
Journal: Frontiers in Psychology
Year: 2024

“Effectiveness of Biobehavioral Therapeutic Education in Chronic Low Back Pain Intensity and Disability: A Systematic Review”

Authors: David Ruíz-del Río, Roy La Touche, Gwendoline Giolito, Silvia Di-Bonaventura, Mónica Grande-Alonso, Álvaro Reina Varona
Journal: Journal of MOVE and Therapeutic Science
Year: 2024

“Can a Specific Biobehavioral-Based Therapeutic Education Program Lead to Changes in Pain Perception and Brain Plasticity Biomarkers in Chronic Pain Patients? A Study Protocol for a Randomized Clinical Trial”

Authors: Silvia Di Bonaventura, Stephen D. Ginsberg, Josué Fernández Carnero, Raúl Ferrer-Peña
Journal: PLOS ONE
Year: 2024

“Effect of Different Physical Therapy Interventions on Brain-Derived Neurotrophic Factor Levels in Chronic Musculoskeletal Pain Patients: A Systematic Review”

Authors: Silvia Di-Bonaventura, Josué Fernández-Carnero, Luis Matesanz-García, Alberto Arribas-Romano, Andrea Polli, Raúl Ferrer-Peña
Journal: Life
Year: 2023